KR100875362B1 - 2,4,6-트리아미노-1,3,5-트리아진 유도체 - Google Patents
2,4,6-트리아미노-1,3,5-트리아진 유도체 Download PDFInfo
- Publication number
- KR100875362B1 KR100875362B1 KR1020067005956A KR20067005956A KR100875362B1 KR 100875362 B1 KR100875362 B1 KR 100875362B1 KR 1020067005956 A KR1020067005956 A KR 1020067005956A KR 20067005956 A KR20067005956 A KR 20067005956A KR 100875362 B1 KR100875362 B1 KR 100875362B1
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- gly
- ser
- ala
- pro
- Prior art date
Links
- 0 C*(C=C1)C=Cc2c1[n]nn2 Chemical compound C*(C=C1)C=Cc2c1[n]nn2 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
Claims (10)
- N-[(2-아미노피리딘-4-일)메틸]-N'-(4-플루오로페닐)-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-(4-플루오로페닐)-N'-[(2-메틸아미노피리딘-4-일)메틸]-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-[(2-에틸아미노피리딘-4-일)메틸]-N'-(4-플루오로페닐)-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-(4-플루오로페닐)-N'-[(2-메톡시피리딘-4-일)메틸]-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-[(2-에톡시피리딘-4-일)메틸]-N'-(4-플루오로페닐)-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-(4-플루오로페닐)-N'-[(2-메톡시피리딘-5-일)메틸]-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-(4-플루오로페닐)-N'-[(2-메톡시피리딘-6-일)메틸]-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-(4-플루오로페닐)-N'-페닐-N"-[(피리미딘-2-일)메틸]-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-[(2-아미노피리미딘-4-일)메틸]-N'-(4-플루오로페닐)-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
- N-[(2-아미노피리딘-6-일)메틸]-N'-(4-플루오로페닐)-N"-페닐-1,3,5-트리아진-2,4,6-트리아민 또는 그의 제약학적으로 허용되는 염.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002028844 | 2002-02-05 | ||
JPJP-P-2002-00028844 | 2002-02-05 | ||
PCT/JP2003/001065 WO2003066099A1 (fr) | 2002-02-05 | 2003-02-03 | Derives de 2,4,6-triamino-1,3,5-triazine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047012037A Division KR100581309B1 (ko) | 2002-02-05 | 2003-02-03 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060030922A KR20060030922A (ko) | 2006-04-11 |
KR100875362B1 true KR100875362B1 (ko) | 2008-12-22 |
Family
ID=27677870
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067005956A KR100875362B1 (ko) | 2002-02-05 | 2003-02-03 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
KR1020047012037A KR100581309B1 (ko) | 2002-02-05 | 2003-02-03 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047012037A KR100581309B1 (ko) | 2002-02-05 | 2003-02-03 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
Country Status (12)
Country | Link |
---|---|
US (2) | US7375222B2 (ko) |
EP (1) | EP1479397B1 (ko) |
JP (1) | JP4325402B2 (ko) |
KR (2) | KR100875362B1 (ko) |
CN (3) | CN1625410A (ko) |
AT (1) | ATE511858T1 (ko) |
AU (1) | AU2003244463A1 (ko) |
CA (1) | CA2475432C (ko) |
ES (1) | ES2364645T3 (ko) |
MX (1) | MXPA04007590A (ko) |
PT (1) | PT1479397E (ko) |
WO (1) | WO2003066099A1 (ko) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5380035A1 (es) * | 2001-03-23 | 2004-03-31 | Aventis Pharma Sa | Derivados quimicos y su aplicacion como agente antitelomerasa |
US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
ATE511858T1 (de) * | 2002-02-05 | 2011-06-15 | Astellas Pharma Inc | 2,4,6-triamino-1,3,5-triazin-derivat |
CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
WO2005003103A2 (en) * | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
CN1629157A (zh) * | 2003-12-19 | 2005-06-22 | 中国科学院上海药物研究所 | 哌嗪三嗪类化合物、其制备方法及药物组合物 |
ITMI20050222A1 (it) * | 2005-02-15 | 2006-08-16 | Milano Politecnico | Lipidi cationici per la trasfezione di acidi nucleici |
WO2007019344A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds |
US8030332B2 (en) * | 2006-02-01 | 2011-10-04 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
WO2007095812A1 (fr) * | 2006-02-27 | 2007-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Composés triazine [1,3,5] substitués, procédés de préparation et utilisations de ceux-ci |
WO2008016547A2 (en) * | 2006-07-31 | 2008-02-07 | Praecis Pharmaceuticals Incorporated | Aurora kinase inhibitors from an encoded small molecule library |
EP2425840B1 (en) * | 2006-12-15 | 2015-04-08 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
JP2010518083A (ja) * | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | ピペリジン誘導体 |
US8258295B2 (en) * | 2007-04-30 | 2012-09-04 | Prometic Biosciences Inc. | Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives |
US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
KR20100038108A (ko) * | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
US8212045B2 (en) | 2007-09-21 | 2012-07-03 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
JP5411867B2 (ja) * | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規sEH阻害剤およびそれらの使用 |
EP2217068A4 (en) * | 2007-10-11 | 2011-09-14 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
KR101546111B1 (ko) * | 2007-10-11 | 2015-08-20 | 글락소스미스클라인 엘엘씨 | 신규한 sEH 억제제 및 그의 용도 |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
CN101952275B (zh) | 2008-02-22 | 2014-06-18 | 弗·哈夫曼-拉罗切有限公司 | β-淀粉样蛋白的调节剂 |
WO2010040661A1 (en) * | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
CN102209537A (zh) | 2008-11-10 | 2011-10-05 | 弗·哈夫曼-拉罗切有限公司 | 杂环γ分泌酶调节剂 |
CA2660954A1 (en) * | 2009-03-31 | 2010-09-30 | Astellas Pharma Inc. | Novel salt of 1,3,5-triazine-2,4,6-triamine derivative |
CA2660962A1 (en) * | 2009-03-31 | 2010-09-30 | Astellas Pharma Inc. | Novel pharmaceutical composition for treatment of schizophrenia |
US8399663B2 (en) * | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
US20100256152A1 (en) * | 2009-04-03 | 2010-10-07 | Astellas Pharma Inc. | Novel pharmaceutical composition for treatment of schizophrenia |
JPWO2010137689A1 (ja) * | 2009-05-29 | 2012-11-15 | アステラス製薬株式会社 | 注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物 |
EP2440057A4 (en) * | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
EP2488032B1 (en) * | 2009-09-23 | 2016-11-02 | Albert Einstein College of Medicine, Inc. | Prostaglandin transporter inhibitors and uses thereof |
EP2332926A1 (en) * | 2009-11-23 | 2011-06-15 | Borealis Agrolinz Melamine GmbH | Melamine based Mannich-compounds and a process for obtaining the same |
US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
CN102070619B (zh) * | 2010-11-29 | 2013-06-05 | 河北大学 | 一种三嗪衍生物及制备方法和其在植物抗菌剂中的应用 |
JP2012153674A (ja) * | 2011-01-28 | 2012-08-16 | Astellas Pharma Inc | ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体 |
KR101472083B1 (ko) * | 2012-10-22 | 2014-12-16 | 광주과학기술원 | ENOblock을 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물 |
EP2774922A1 (en) * | 2013-03-04 | 2014-09-10 | Borealis Agrolinz Melamine GmbH | Method for obtaining a functionalized triazine compound and the triazine compound obtained by said method |
US9914709B2 (en) * | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
BR112015033042B1 (pt) | 2013-07-16 | 2020-10-13 | Basf Se | composto de azina, processos para a preparação de composto de azina, composição agroquímica, processo para a preparação de composições agroquímicas, método para controlar vegetação e uso do composto de azina |
EP3122736A1 (en) * | 2014-03-28 | 2017-02-01 | Basf Se | Diaminotriazine derivatives as herbicides |
EP3129359B1 (en) | 2014-04-11 | 2021-03-03 | Basf Se | Diaminotriazine derivatives as herbicides |
US10029992B2 (en) | 2014-04-23 | 2018-07-24 | Basf Se | Diaminotriazine compounds and their use as herbicides |
WO2015162169A1 (en) | 2014-04-23 | 2015-10-29 | Basf Se | Diaminotriazine compounds as herbicides |
WO2016059647A2 (en) * | 2014-10-13 | 2016-04-21 | SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) | Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1 |
CN105294588A (zh) * | 2015-11-25 | 2016-02-03 | 武汉工程大学 | 含氟三嗪衍生物及其制备方法和用途 |
WO2018230595A1 (ja) * | 2017-06-14 | 2018-12-20 | 富士フイルム株式会社 | 組成物、膜、レンズ、固体撮像素子、化合物 |
CN108276351A (zh) * | 2018-02-11 | 2018-07-13 | 天津大学 | 具有潜在抗癌效果化合物及其测定方法 |
KR102022323B1 (ko) * | 2018-03-30 | 2019-09-18 | 정하윤 | 트리아진 화합물 및 이의 용도 |
CN111662242B (zh) * | 2019-03-08 | 2023-10-24 | 中国药科大学 | 杂环类idh突变体抑制剂、其制备方法及用途 |
CN112759557B (zh) * | 2019-11-04 | 2023-12-29 | 圣奥化学科技有限公司 | 具有抗老化和耐变色功效的化合物及其制备方法 |
KR20230040022A (ko) * | 2021-09-15 | 2023-03-22 | 주식회사 펩토이드 | 다제 내성균 항균 조성물 및 그의 제조방법 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB951667A (en) | 1961-04-25 | 1964-03-11 | Ici Ltd | New water soluble azo dyestuffs containing quaternary ammonium groups |
JPS5111861Y2 (ko) | 1971-06-11 | 1976-03-31 | ||
DE3440777C2 (de) * | 1983-11-14 | 1998-09-03 | Clariant Finance Bvi Ltd | Neue sulfonsäuregruppenhaltige, basische Azoverbindungen, deren Herstellung und Verwendung als Farbstoffe |
JPS61246261A (ja) | 1985-04-25 | 1986-11-01 | Toyo Ink Mfg Co Ltd | 顔料分散剤 |
IL87542A (en) * | 1987-08-28 | 1993-01-31 | Uniroyal Chem Co Inc | Arylenediamino substituted triazine derivatives, processes for the preparation thereof and compositions containing the same |
US4794135A (en) * | 1987-08-28 | 1988-12-27 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted triazines |
CH684948A5 (de) * | 1992-05-13 | 1995-02-15 | Sandoz Ag | Basische sulfogruppenhaltige Disazoverbindungen. |
DE4430094A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel |
US6117996A (en) * | 1995-09-20 | 2000-09-12 | Novo Nordisk A/S | Triazine based ligands and use thereof |
WO1997042267A1 (en) * | 1996-05-03 | 1997-11-13 | Alliedsignal Inc. | Novel nylon compositions |
EP1293504A3 (de) * | 1996-07-08 | 2003-11-05 | Ciba SC Holding AG | Triazinderivate als UV-Filter in kosmetischen Mitteln |
JP3967783B2 (ja) * | 1996-07-31 | 2007-08-29 | 富士フイルム株式会社 | 顔料分散組成物及びそれを用いた着色感光性組成物 |
IT1284525B1 (it) * | 1996-09-13 | 1998-05-21 | 3V Sigma Spa | Derivati di benzossazolo loro uso come stabilizzanti contro le radiazioni uv |
WO1999001442A1 (en) | 1997-07-02 | 1999-01-14 | Zeneca Limited | Triazine derivatives and their use as antibacterial agents |
JPH1143448A (ja) * | 1997-07-09 | 1999-02-16 | Nippon Soda Co Ltd | フェノール系分子化合物を使用する反応方法 |
DE19735800A1 (de) * | 1997-08-18 | 1999-02-25 | Boehringer Ingelheim Pharma | Triazine mit adenosinantagonistischer Wirkung |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6123763A (en) * | 1997-12-22 | 2000-09-26 | Toyo Ink Mfg. Co., Ltd. | Pigment dispersing agent and pigment composition containing the same |
JP3518300B2 (ja) | 1997-11-17 | 2004-04-12 | 東洋インキ製造株式会社 | 顔料分散剤、及びそれを含有する顔料組成物 |
CA2318362A1 (en) | 1998-01-13 | 1999-07-22 | Sharon T. Cload | Triazine antiviral compounds |
US6335339B1 (en) * | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
AU1982799A (en) * | 1998-01-23 | 1999-08-09 | Yamanouchi Pharmaceutical Co., Ltd. | Novel potassium channel protein |
EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
EP1091942B1 (en) * | 1998-07-02 | 2005-03-30 | Neurosearch A/S | Potassium channel blocking agents |
US20020099197A1 (en) * | 1998-07-21 | 2002-07-25 | Rory A.J. Curtis | Novel potassium channel molecules and uses therefor |
EP1178963A1 (en) * | 1999-05-12 | 2002-02-13 | Neurosearch A/S | Ion channel modulating agents |
US6262053B1 (en) * | 1999-06-23 | 2001-07-17 | Parker Hughes Institute | Melamine derivatives as potent anti-cancer agents |
AU5390900A (en) * | 1999-06-29 | 2001-01-22 | Neurosearch A/S | Potassium channel blocking agents |
AU775360B2 (en) | 1999-09-24 | 2004-07-29 | Janssen Pharmaceutica N.V. | Antiviral compositions |
WO2001066743A2 (en) * | 2000-03-03 | 2001-09-13 | Millennium Pharmaceuticals, Inc. | A potassium channel molecule and uses therefor |
US6630469B2 (en) * | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
MXPA04002397A (es) | 2001-09-14 | 2004-12-02 | Methylgene Inc | Inhibidores de histona deacetilasa. |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
MXPA04002680A (es) | 2001-09-21 | 2004-06-18 | Reddy Therapeutics Inc | Metodos y composiciones de compuestos de triazina novedosos. |
WO2003041496A1 (fr) * | 2001-11-14 | 2003-05-22 | Yamanouchi Pharmaceutical Co., Ltd. | Animal transgenique |
ATE511858T1 (de) * | 2002-02-05 | 2011-06-15 | Astellas Pharma Inc | 2,4,6-triamino-1,3,5-triazin-derivat |
-
2003
- 2003-02-03 AT AT03737464T patent/ATE511858T1/de active
- 2003-02-03 AU AU2003244463A patent/AU2003244463A1/en not_active Abandoned
- 2003-02-03 JP JP2003565522A patent/JP4325402B2/ja not_active Expired - Fee Related
- 2003-02-03 CA CA2475432A patent/CA2475432C/en not_active Expired - Fee Related
- 2003-02-03 US US10/503,494 patent/US7375222B2/en not_active Expired - Fee Related
- 2003-02-03 EP EP03737464A patent/EP1479397B1/en not_active Expired - Lifetime
- 2003-02-03 PT PT03737464T patent/PT1479397E/pt unknown
- 2003-02-03 KR KR1020067005956A patent/KR100875362B1/ko not_active IP Right Cessation
- 2003-02-03 MX MXPA04007590A patent/MXPA04007590A/es active IP Right Grant
- 2003-02-03 KR KR1020047012037A patent/KR100581309B1/ko not_active IP Right Cessation
- 2003-02-03 CN CNA038031310A patent/CN1625410A/zh active Pending
- 2003-02-03 CN CN201110039025.9A patent/CN102151273B/zh not_active Expired - Fee Related
- 2003-02-03 ES ES03737464T patent/ES2364645T3/es not_active Expired - Lifetime
- 2003-02-03 WO PCT/JP2003/001065 patent/WO2003066099A1/ja active Application Filing
- 2003-02-03 CN CNA2006100958976A patent/CN1939307A/zh active Pending
-
2008
- 2008-02-06 US US12/027,246 patent/US20080227785A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE511858T1 (de) | 2011-06-15 |
CN102151273B (zh) | 2015-11-25 |
MXPA04007590A (es) | 2004-12-06 |
US20080227785A1 (en) | 2008-09-18 |
US7375222B2 (en) | 2008-05-20 |
KR20060030922A (ko) | 2006-04-11 |
WO2003066099A1 (fr) | 2003-08-14 |
KR100581309B1 (ko) | 2006-05-22 |
KR20040081485A (ko) | 2004-09-21 |
PT1479397E (pt) | 2011-09-01 |
ES2364645T3 (es) | 2011-09-08 |
EP1479397A4 (en) | 2009-01-07 |
CN1625410A (zh) | 2005-06-08 |
JPWO2003066099A1 (ja) | 2005-05-26 |
EP1479397A1 (en) | 2004-11-24 |
EP1479397B1 (en) | 2011-06-08 |
CA2475432A1 (en) | 2003-08-14 |
CN102151273A (zh) | 2011-08-17 |
US20060194803A1 (en) | 2006-08-31 |
CN1939307A (zh) | 2007-04-04 |
AU2003244463A1 (en) | 2003-09-02 |
CA2475432C (en) | 2011-04-05 |
JP4325402B2 (ja) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100875362B1 (ko) | 2,4,6-트리아미노-1,3,5-트리아진 유도체 | |
US10370363B2 (en) | Inhibitors of CXCR2 | |
JP5233996B2 (ja) | ジ(アリールアミノ)アリール化合物 | |
HUE026705T2 (en) | Compounds for reducing beta-amyloid production | |
WO2010057006A9 (en) | Azaquinolinone derivatives and uses thereof | |
JP2010184946A (ja) | 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物 | |
CN110662745B (zh) | 吡咯并吡啶衍生物、其制备方法、和用于预防或治疗蛋白激酶相关疾病的药物组合物 | |
CN110248935A (zh) | 用于治疗疼痛和疼痛相关病症的含氮二环衍生物 | |
JP7336434B2 (ja) | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 | |
CA3149989A1 (en) | Methods of treating epilepsy using the same | |
US10793575B2 (en) | Oxoisoquinoline derivatives | |
TW201802073A (zh) | 用於治療疾病之神經醯胺半乳糖基轉移酶抑制劑 | |
ES2360014T3 (es) | Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina. | |
US20130109711A1 (en) | Novel compounds | |
EP4052706A1 (en) | Composition for preventing or inhibiting axonal degeneration | |
US6482819B1 (en) | 2,3-benzodiazepine derivatives | |
KR102352624B1 (ko) | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 | |
CN117362304A (zh) | 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用 | |
TW202416971A (zh) | 甲醯胺取代的雜三環類衍生物、其製備方法及其應用 | |
US20130116270A1 (en) | Novel compounds | |
US20160102088A1 (en) | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121121 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131118 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141120 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151118 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171117 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |